BRILL-EU Study · NX-BRI-002
This European, non-interventional study assesses treatment satisfaction, preferences, quality of life, and tolerability of Briumvi® in patients with active relapsing multiple sclerosis. Data is collected within routine clinical practice settings.
Non-interventional, prospective, multicenter, European study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice
Sponsor: NEURAXPHARM
Phase: IV
Status: Follow-up